Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP trial: sequence treatment in HER2-positive pertuzumab-pretreated advanced breast cancer
2019-002181-12Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab emtansine in HER2-positive breast cancer (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Progression-free survival. Started May 2021; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2019-002181-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002181-12.